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Abstract
Background: Memory responses require immune competence. We assessed the influence of priming with AS03-adjuvanted
pandemic vaccine (PandemrixH) on memory responses of HIV patients, kidney recipients (SOT) and healthy controls (HC).
Method: Participants (HIV: 197, SOT: 53; HC: 156) were enrolled in a prospective study and 390/406 (96%) completed it. All
had been primed in 2009/2010 with 1 (HC) or 2 (patients) doses of PandemrixH, and were boosted with the 2010/2011
seasonal influenza vaccine. Geometric mean titres and seroprotection rates were measured 12 months after priming and 4
weeks after boosting. Primary and memory responses were directly compared in 191 participants (HCW: 69, HIV: 71, SOT: 51)
followed during 2 consecutive seasons.
Results: Most participants (HC: 77.8%, HIV: 77.6%, SOT: 66%) remained seroprotected at 12 months post-priming. Persisting
A/09/H1N1 titers were high in HIV (100.2) and HC (120.1), but lower in SOT (61.4) patients. Memory responses reached
higher titers in HIV (507.8) than in HC (253.5) and SOT (136.9) patients. Increasing age and lack of HAART reduced persisting
and memory responses, mainly influenced by residual antibody titers. Comparing 2009/2010 and 2010/2011 titers in 191
participants followed for 2 seasons indicated lower post-2010/2011 titers in HC (240.2 vs 313.9), but higher titers in HIV
(435.7 vs 338.0) and SOT (136 vs 90.3) patients.
Conclusions: Priming with 2 doses of PandemrixH elicited persistent antibody responses and even stronger memory
responses to non-adjuvanted seasonal vaccine in HIV patients than 1 dose in healthy subjects. Adjuvanted influenza
vaccines may improve memory responses of immunocompromised patients.
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Introduction
Immunosuppressed patients are at higher risks of influenza
complications. This was evidenced by reports of disease outcome
in solid organ transplant (SOT) recipients infected by the
pandemic influenza A/09/H1N1 strain [1–6]. A similar risk
exists in HIV infected individuals with advanced disease and low
CD4 cell count but not in HAART-treated patients [7–11].
Immunosuppressed patients have a general trend toward
impaired antibody responses to non-adjuvanted vaccines [6].
Short-term antibody responses were indeed lower following 1 or 2
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doses of non-adjuvanted influenza A/09/H1N1 vaccines in HIV-
infected [12,13] and solid organ transplant (SOT) patients [13–
15]. The extent to which adjuvanted vaccines may improve
responses is thus of central interest. In HIV-infected patients, a
single dose of the AS03-adjuvanted pandemic vaccine (Pandem-
rixH) elicited higher responses than non-adjuvanted monovalent
vaccines [16]. Four weeks after 1 dose of PandemrixH, seror-
esponses remained lower than in controls [17,18] reaching similar
titers after 2 doses [19–21]. Seroresponses remained lower in SOT
recipients even after 2 doses of PandemrixH [19,22,23], reflecting a
more profound impact of immunosuppression on vaccine
responses.
How immunosuppression affects memory responses is less well
defined. In HIV-infected patients, impaired B and T cell functions
cause dysfunctional germinal center interactions [24] and result in
a progressive loss of B-cell memory despite antiretroviral therapy
[25–27]. Accordingly, most HAART-treated HIV-infected adults
reached a hemagglutination inhibition titer (HAI) $1/40 four
weeks after immunization with non-adjuvanted A/09/H1N1
vaccines but only 28% remained above this threshold at 6 months
[28]. How the immunosuppression of SOT patients affects
memory responses is less well described.
In 2009/2010, we had followed 760 immunocompromised and
133 healthy adults immunized with 1 (healthy) or 2 (patients) doses
of PandemrixH. Four weeks after immunization, we observed
similar responses in HIV-infected individuals after 2 doses as in
healthy adults after 1 dose [20], and lower seroresponses in SOT
recipients despite 2 immunizations [23]. To define how adju-
vanted vaccines would influence antibody persistence and memory
responses, we assessed the impact of 2009/2010 priming with
PandemrixH on antibody persistence and memory responses
elicited in 2010/2011 by one dose of a non-adjuvanted trivalent
inactivated seasonal vaccine including the same influenza A/09/
H1N1 strain.
Patients and Methods
Subjects
This prospective, multisite, open-label study recruited 406
subjects in November 2010:197 HIV-infected patients, 53 SOT
(kidney) recipients and 156 healthy controls (HC) (Figure S1).
Inclusion criteria included age above 18 years and having received
1 (controls) or 2 (patients) doses of AS03-adjuvanted pandemic
influenza vaccine in 2009/2010. Among these 406 subjects, 191
subjects (69 HIV-infected patients, 51 kidney transplant recipients
and 71 controls) had already been enrolled in 2009/2010 and
were followed for 2 seasons. The latter are referred to as the 2009–
2010–2011 cohort. The study was approved by the institutional
review board (ID: CER-09-234), registered on ClinicalTrials.gov
prior to patient enrolment (ID: NCT01022905) and conducted in
accordance with the principles of the Declaration of Helsinki, the
standards of Good Clinical Practice, and Swiss regulatory
requirements. Written informed consent was obtained prior to
inclusion in 2009 and in 2010.
The protocol for this trial is available as supporting information,
see Protocol S1.
Vaccines and Immunizations
In 2010/2011, patients and controls received one intramuscular
dose of a non-adjuvanted trivalent split-virus influenza vaccine
containing 15 mg of A/California/07/2009 (H1N1), A/Perth/16/
2009 (H3N2) and B/Brisbane/60/2008. Most patients (.98% in
each group) received MutagripH (SanofiPasteurMSD). In 2009/
2010, all participants had received 1 (healthy controls) or 2 doses
(HIV-infected or SOT patients) of AS03-adjuvanted split-virus
influenza A/09/H1N1 vaccine (PandemrixH, GlaxoSmithKline)
at a 4 weeks interval, according to official Swiss recommendations.
Each dose of PandemrixH contained 3.75 mg of A/09/H1N1
antigen emulsified in squalene, DL-a´-tocopherol and polysorbate
80.
Data Collection
Medical information was obtained through a detailed medical
history and completed through the patient’s records. Blood was
collected on the day of the first dose and 4 weeks after
immunization. Sera were prepared and stored at -20uC until used.
Haemagglutination Inhibition (HAI) Assay
HAI assays were performed as described [29]. Sera were
subjected to 2-fold serial dilutions prior to incubation with 4 or 8
HA units of pandemic influenza A/California/7/09 (H1N1) and
seasonal A/Perth/09 (H3N2) virus, respectively. Results were
expressed as the reciprocal of the highest dilution showing a
positive HAI. Negative samples were assigned a titre of 1:4 and
individual values were log transformed to calculate the geometric
mean antibody titres (GMT).
The three co-primary immunogenicity end-points were: 1) The
GMTs based on individual HAI titres, 2) the proportion of
seroprotected subjects (defined as a post-vaccination HAI-titre of
$1:40) and 3) the proportion of subjects with a seroresponse
(defined as a post-vaccination HAI-titre of $1:40 and a fold
increase in GMT of $4 between pre-vaccination and post-
vaccination HAI- titres).
Safety Monitoring
Safety endpoints were divided into local inflammation (injec-
tion-site pain, erythema and swelling) and systemic reactions
(fever, fatigue, headaches and anorexia). They were self-recorded
for 7 days after each dose. Serious adverse events (SAE) were
actively searched for and followed up until their resolution;
recording stopped on February 28, 2010, at study termination. In
HIV-infected patients, HIV-RNA levels were measured 4 weeks
after immunization to detect potential increases in HIV-RNA
levels. Quantitative plasma HIV-1 RNA was measured on a
Roche COBAS TaqMan HIV-1 test version 2.0 (Roche Diagnos-
tic, Basel, Switzerland). Transplant patients were closely followed
and instructed to contact the study investigator in case of adverse
events.
Statistical Analysis
Due to the lack of data concerning the long-term immunoge-
nicity of PandemrixH at time of study design, sample size was
based on recruitment capacity. GMTs were given with 95%
confidence interval. The reverse cumulative distributions were
presented. The comparison of titres between individual strata was
assessed by means of the Kruskal-Wallis test. For longitudinal
comparisons, the Wilcoxon test for paired data was used (for
instance baseline vs post-baseline titers from same patients).
Comparisons of proportions were performed by using Chi-squared
tests (or Fisher exact test if frequencies were less than 5) and
McNemar tests for paired data. Multivariate regression models
were constructed to investigate the association between specific
independent variables and post-vaccination antibody titres. The
selection of factors introduced in the models was determined a
priori. Data were logarithmically transformed prior to analysis.
The parameter of the linear model indicated the variation on the
log-transformed titre and we interpreted the meaning of the
Memory Responses to Pandemic Influenza Vaccine
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regression parameters as the percentage increase of the titre per
given unit (for continuous factors) or compared to the reference
category (for categorical factors). A logistic regression was
performed to assess the association of the gender on the risk of
pain adjusted on the group of patients. An odds ratio greater than
1 was interpreted as an increase of risk in women compared to
men. The significance level was defined as 0.05. Data were
analysed by using S-PLUS 8.0, Insightful Corp., Seattle, WA
(USA).
Results
Characteristics of Immunosuppressed Patients and
Healthy Subjects
The clinical characteristics of the 197 HIV-infected patients, 53
SOT recipients and 156 healthy controls recruited in 2010/2011
are described in Table 1. All had been immunized with
PandemrixH in 2009/2010. HCs included a higher percentage
of females and were younger. Most participants were Caucasians
(82%) and had been immunized against seasonal influenza in
2009. HIV-infected patients were characterized by their CDC
category, CD4 T cell count and nadir (Table 1). Most were
treated with antiretroviral drugs. Kidney transplant recipients had
reduced creatinine clearance (median 52, IQR 38–60). Most were
on maintenance mycophenolate acid, tacrolimus and low dose
steroids (Table 1). All had been transplanted more than one year
ago (median 9.1 years, IQR 4.8–13.4), minimum 1.3 year). Two
had been treated for a rejection episode within 12 months (40 and
351 days before immunization).
All participants but one HC (newly recognized pregnancy)
received a single dose of a non-adjuvanted trivalent inactivated
2010–2011 seasonal influenza vaccine, mostly MutagripH, allow-
ing to directly compare their 2010–2011 responses despite
differences in their 2009 immunization history. Seven HIV-
positive patients and 1 SOT recipient remained unreachable. One
SOT patient died of a non-vaccine related event. Six HCs
withdrew consent to the 2nd blood sample. Altogether, 190/197
(96.4%) of HIV patients, 51/53 (96.2%) of SOT recipients and
149/156 (95.5%) healthy subjects were included in the 2010/2011
analysis of vaccine responses (Figure S1).
Safety
Immunization was generally well tolerated (Table S1). Local
pain was more frequently reported by HCs (59.7% (CI95% 51.4;
67.7)) than HIV (42.1 (CI95% 35; 49.5)) or SOT (35.3 (CI95%
22.4; 49.9), p,0.001) patients. Women reported pain more
frequently than men (OR adjusted on group: 2.06, CI95% 1.34–
3.17), p,0.001) and, despite the higher proportion of women
among HCs, the group effects remained significant: OR=0.62
(CI95% 0.39–0.98,p= 0.04) for HIV compared to HCs and
OR=0.43 (CI95% 0.22–0.85, p= 0.02) for kidney recipients
compared to HCs. Systemic reactions were rare and evenly
distributed. Four weeks after immunization, HIV-RNA were below
detection levels (172/197, 93%) or low (median 136 copies/mL,
IQR 58–3048). SOT patients did not require any change of their
immunosuppression regimen. Two severe adverse events (1 death,
1 amputation) were considered as unrelated to immunization.
Antibody Persistence 12 Months after Monovalent AS03-
adjuvanted Influenza A/09/H1N1 Immunization
Antibody titers persisting 12 months after PandemrixH immu-
nization were assessed by HAI in 153/156 (98.0%) HCs, 196/197
(99.5%) HIV patients and all (53) kidney recipients. Most
participants (HIV: 77.6%; HC: 77.8%; SOT 66%) remained
seroprotected. Residual HAI-GMTs (pre-2010) were as high in
HIV patients (100.2, CI95% 86.3–116.2) as in HCs (120.1, CI95%
99.7–144.6). Despite 2 doses of PandemrixH, titers were lower in
SOT recipients (61.4, CI95% 44.0-85.7) than in HIV patients or
controls (Table 2A and Figure 1 A–B).
Regression analyses indicated that increasing age significantly
lowered antibody persistence, reflected by lower pre-2010 HAI-
GMTs (Table 3) and seroprotection rates (HC .60 years: 36.4%
(CI95% 10.9-69.2) vs 81.0% (CI95% 73.6-87.1) for subjects #60
years, p=0.003; HIV.60 years: 63.3% (CI95% 43.9-80.1) vs 80.1%
(CI95% 73.2-85.9) for subjects #60 years, p=0.07). Multivariate
analyses (Table 4) confirmed that each additional 10 years reduced
pre-2010 HAI-GMTs, although not significantly in HIV patients.
Antibodies persisted at higher titers in HIV patients with CD4 counts
.350/mm3 or HAART treated (Table 4). The immunosuppression
regimens were too homogenous to lead to significant drug-specific
influences (Table 3 and 4). Gender and 2009/2010 seasonal
influenza immunization exerted no impact (not shown).
Memory Responses to Influenza A/09/H1N1
Immunization during the 2010/2011 Season
Four weeks after boosting with 1 dose of non-adjuvanted
inactivated 2010–2011 trivalent vaccine including again the
influenza A/09/H1N1 strain, HAI-GMTs had significantly
increased in each group (Figure 1A–C). HCs raised strong
responses (fold increase 2.07 (CI95% 1.81-2.37), p,0.001) and
reached higher seroprotection rates (95.8 (CI95% 91.2-98.5) vs
77.8 (CI95% 70.4-84.1), p,0.001) compared to baseline
(Figure 1A and Table 2A). Antibody responses were even
stronger in HIV patients (fold increase 4.99 (4.22; 5.91,
p,0.001), their post-immunization HAI titers reaching 2-fold
higher levels than those of HCs (p,0.001), and a remarkable
98.4% (CI95% 95.4-99.7) seroprotection rate. One dose of
seasonal 2010/2011 vaccine also increased the HAI titers of
SOT recipients (fold increase 2.83 (1.64; 3.19), p,0.001).
However, HAI-titers and seroprotection rates remained lower
than in controls (Table 2A). Despite adjustment for age, HAI-
titers also remained 65.7% lower in SOT than in HIV patients
(p,0.001) similarly primed in 2009 with 2 doses of Pandem-
rixH, reflecting their lower immune competence. Seroconversion
rates, less informative when baseline antibodies are high, were
significantly higher in HIV patients (Table 2A) despite similar
pre-2010 HAI-GMTs, reflecting superior memory responses.
Increasing age significantly impacted the post-2010 antibody
responses: each additional 10 years independently reduced post-
immunization titers by 20% (HC), 22% (HIV) or 29% (SOT)
(Table 4). Antibody responses appeared paradoxically better in
HIV patients with more advanced disease (Table 3), but
multivariate analyses identified HAART as independently associ-
ated with higher vaccine responses (Table 4). Memory responses
were lower in MMF-treated patients (-42%), without reaching
statistical significance.
The strongest determinant of the 2010/2011 antibody responses
was the residual (pre-2010) antibody titer. This influence was
positive: post-2010 titers were significantly higher (p,0.001) when
persisting antibodies were above as compared to below the group
median (Table 3). Adding persisting antibodies in the regression
analyses indicated that they increased post-2010/2011 titers by
97% (HC), 69.6% (HIV) and 137.6% (SOT) (not shown). As post-
2010/2011 HAI-GMT were significantly higher in HIV patients
compared to HCs after controlling for age, gender and pre-2010
titers (p,0.001), we focused subsequent analyses on participants
followed during 2 seasons.
Memory Responses to Pandemic Influenza Vaccine
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Influence of 2009/2010 Immunization on 2010/2011
Memory Responses to Influenza A/09/H1N1
HAI titers elicited in 2009/2010 (post-2009), persisting in 2010/
2011 (pre-2010) and reactivated in 2010/2011 (post-2010) were
compared for the 191 patients of the 2009/2010/2011 cohort
(HC: 69, HIV: 71, SOT: 51) (Table 2B and Figure 1E).
As described [20,23], post 2009/2010 HAI-GMTs were
similar in HIV individuals and HCs, and lower in SOT
recipients (Table 2B and Figure 1E). HAI-GMTs declined
during the following year and increased after the 2010/2011
immunization. In HCs, post-2010/2011 HAI titers remained
significantly lower than in 2009/2010 (240.2 vs 313.9, p,0.001)
(Table 2B and Figure 1E). In contrast, higher HAI-GMTs
were observed in HIV patients following boosting with 1 dose of
seasonal 2010/2011 vaccine as compared to priming with 2
doses of PandemrixH (HAI: 435.7 vs 338.0, p= 0.03; post-2010/
post-2009 GMT ratio: 1.365 (1.034; 1.803), p = 0.03). A similar
trend towards higher post-2010/2011 responses was observed in
SOT recipients (HAI: 136.0 vs 90.3, p= 0.20; GMT ratio 1.502
(0.992; 2.275), p = 0.055). These better 2010/2011 than 2009/
2010 responses were not ascribed to higher immune compe-
tence: changes in the medical conditions (7 patients) or
antiretroviral therapy (13 changes, including 8 changes of drug
class) of HIV patients were not considered as increasing
immune competence, and immunosuppression intensity had
been reduced in 8 but increased in 8 others SOT recipients.
Table 1. Baseline characteristics.
Controls HIV Kidney recipient
Total N 156 197 53 p value*
Women N (%) 106 67.90% 62 31.50% 20 37.70%
Median age, years (IQR) 42.9 (33.8–51.7) 47.6 (40.9–55.3) 61.6 (55.6–69.7) ,0.001
,40 yrs 61 39.10% 44 22.30% 3 5.70% ,0.001
40–60 yrs 84 53.80% 123 62.40% 21 39.60%
.60 yrs 11 7.10% 30 15.20% 29 54.70%
Seasonal influenza 2009 N (%) 148 94.90% 183 92.90% 46 86.80% 0.14
Ethnicity, N (%) Caucasian 148 94.9% 129 65.5% 47 88.7%
Afri. Sub-saharian 4 2.6% 43 21.8% 3 5.7%
Others 4 2.6% 25 12.7% 3 5.7%
CDC category A, N (%) 89 45.40%
B, N (%) 51 26.00%
C, N (%) 56 28.60%
Missing data 1 0.50%
Antiretroviral therapy None 11 5.60%
Including PI, no NNRTI 60 30.50%
Including NNRTI, no PI 84 42.60%
ART+PI+NNRTI 20 10.20%
HAART + other 22 11.20%
CD4 Baseline, cells/mm3 Median (IQR) 615 (458–769)
Missing data 5 2.50%
Nadir, cells/mm3 Median (IQR) 172 (50–288)
Missing data 1 0.50%
Time since transplant, years Median (IQR) 9.1 (4.8–13.4)
Rejection episodes within No 51 96.20%
previous 12 months, N(%) Yes 2 3.80%
Immunosuppressive Cyclosporin, N(%) 11 20.80%
treatment Tacrolimus, N (%) 37 69.80%
Evero- or Sirolimus, N (%) 2 3.80%
MMF or EC-MPA, N (%) 35 66.00%
Azathioprine, N (%) 8 15.10%
Others, N(%) 1 1.90%
Oral steroids N(%) 28 52.80%
Low oral dose (,10 mg) N(%) 25 89.30%
*compared to controls.
IQR: interquartile range; PI: protease inhibitor; NNRTI : Non-Nucleoside Reverse Transcriptase Inhibitors; ART : antiretroviral therapy;
HAART: highly active antiretroviral therapy; MMF: mycophenolate mofetil; EC-MPA: enteric-coated mycophenolic acid.
doi:10.1371/journal.pone.0040428.t001
Memory Responses to Pandemic Influenza Vaccine
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Similar 2010/2011 Antibody Responses to Influenza A/
09/H3N2 in HIV-infected and Healthy Subjects
To compare the immune competence of HIV and HCs during
the 2010/2011 season, we assessed primary antibody responses to
the influenza A/09/H3N2 strain, first included in the 2010–2011
seasonal trivalent vaccine. H3N2 HAI-GMTs and seroprotection
rates were low prior to immunization and increased following
immunization (Table 2C and Figure 1F). H3N2 HAI-GMTs
remained relatively low and responses were not significantly
different among patients and controls (Table 2C and Figure 1F).
Figure 1. Distribution and kinetics of antibody titers. A–C. Blood was collected before and 4 weeks after 1 dose of non-adjuvanted 2010/2011
seasonal influenza vaccine. Antibody titers were assessed by hemagglutination inhibition (HAI). The results were expressed as the reciprocal of the
highest dilution showing a positive HAI (see Methods). The vertical dotted line represents the seroprotection threshold (titer 1:40). The curves
represent the distribution of individual antibody titers in each group. D-F: Geometric mean HAI titers to influenza A/09/H1N1 (D, E) and A/09/H3N2 (F)
were measured before (pre-2009) and after (post-2009) immunization with 1 (controls) or 2 (patients) doses of AS03-adjuvanted pandemic vaccine,
and before (pre-2010) and after (post-2010) 1 dose of non-adjuvanted 2010/2011 seasonal influenza vaccine. D: All patients followed in 2010/2011. E -
F: Patients followed for 2 consecutive seasons.
doi:10.1371/journal.pone.0040428.g001
Memory Responses to Pandemic Influenza Vaccine
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Thus, true anamnestic responses characterized by stronger booster
2010/2011 than primary 2009/2010 responses against influenza
A/09/H1N1 were observed in well-controlled HAART-treated
HIV patients and moderately immunosuppressed SOT recipients,
but not in healthy individuals.
Discussion
How immune competence affects memory responses and
whether these may be enhanced by adjuvanted vaccines is not
well known. Here we show that antibodies elicited by the AS03-
adjuvanted pandemic vaccine (PandemrixH) persisted at similarly
high titers in HIV patients as in HCs up to 12 months after
priming. Unexpectedly, memory responses elicited against A/09/
H1N1 by non-adjuvanted trivalent 2010/2011 influenza vaccines
were stronger in HIV patients primed in 2009 with 2 doses of
PandemrixH than in HCs primed with a single dose. Persisting
antibody titers and memory responses were also high – although
significantly lower - in SOT recipients.
The duration of vaccine-induced antibodies depends upon peak
antibody production by short-lived plasma cells and plasma
cell persistence. The rapid disappearance of vaccine antibodies
usually observed in HIV patients, as following immunization with
non-adjuvanted pandemic vaccines [28], may thus result from low
peak responses and/or short-lasting antibody production. In
contrast to the conclusion of Cagigi et al [24] that ‘‘even if
immunisation induces a good antibody response, patients with
HIV will not sustain antibody production for as long as healthy
individuals because of intrinsic defects in their B cell compart-
ment’’, HAI antibodies persisted at similarly high levels in HIV
patients and HCs and remained above seroprotective levels in
most SOT recipients. We cannot formally demonstrate that this
resulted from priming with PandemrixH, as non-adjuvanted
pandemic vaccines were unavailable in Switzerland. However,
antibody persistence was better following immunization with
AS03-adjuvanted than non-adjuvanted H5N1 vaccines (seropro-
tection rate 36% vs 6%) [30]. As younger age, antiretroviral
therapy and higher CD4 counts favoured antibody persistence,
shorter/weaker responses might have been observed in non-
HAART treated patients.
Controls reached lower titers following boosting in 2010/2011
than priming in 2009/2010, reflecting the recruitment/activation
of fewer antigen-specific B cells by 15 ug of non-adjuvanted than
3.8 ug of AS03-adjuvanted H1N1 antigens. These weaker 2010/
2011 responses did not result from an inhibitory influence of
higher baseline antibodies, which were positively correlated with
booster responses. They are unlikely to reflect altered immune
Table 2. Antibody persistence and memory responses to influenza A/09/H1N1 and A/09/H3N2.
Influenza A/09/H1N1 HAI-GMT Seroprotection Seroconversion
A. 2010/2011 cohort N (95%CI) N (%) N/Total (%)
Controls Pre 2010 153 120.1 (99.7;144.6) 119 77.8 (70.4;84.1)
Post 2010 144 253.5 (213.4;301.1) 138 95.8 (91.2;98.5) 66/142 46.5 (38.1;55.0)
HIV Pre 2010 196 100.2 (86.3;116.2) 152 77.6 (71.1;83.2)
Post 2010 187 507.8 (428.7;601.4)*** 184 98.4 (95.4;99.7) 148/186 79.6 (73.1;85.1) ***
Kidney recipients Pre 2010 53 61.4 (44;85.7) ** 35 66 (51.7;78.5)
Post 2010 51 136.9 (89.7;209.1)* 37 72.5 (58.3;84.1) *** 20/51 39.2 (25.8;53.9)
B. 2009/2010/2011 cohort
Controls Post 2009 69 313.9 (218.6;450.8) 60 88.2 (78.1;94.8)
Pre 2010 69 121.1 (93.0;157.6) 55 79.7 (68.3;88.4)
Post 2010 69 240.2 (188.4;306.1) 67 97.1 (89.9;99.6) 27/67 40.3 (28.5;53.0)
HIV Post 2009 66 338.0 (252.8;451.9) 62 93.9 (85.2;98.3)
Pre 2010 70 90.4 (70.1;116.6) 55 78.6 (67.1;87.5)
Post 2010 68 435.7 (320.8;591.9)*** 65 95.6 (87.6;99.1) 49/67 73.1 (60.9;83.2) ***
Kidney recipients Post 2009 52 90.3 (58.9;138.2) *** 35 67.3 (52.9;79.7)
Pre 2010 52 60.2 (42.9;84.4) ** 34 65.4 (50.9;78.0)
Post 2010 50 136.0 (88.3;209.4)* 36 72.0 (57.5;83.8) *** 20/50 40 (26.4;54.8)
Influenza A/09/H3N2 HAI-GMT Seroprotection Seroconversion
C. 2009/2010/2011 cohort N (95%CI) N (%) N/Total (%)
Controls Pre 2010 69 23.2 (16.5;32.6) 30 43.5 (31.6;56.0)
Post 2010 69 71.1 (51.1;98.9) 48 69.6 (57.3;80.1) 31/69 44.9 (32.9;57.4)
HIV Pre 2010 67 30.2 (21.9;41.7) 29 43.3 (31.2;56.0)
Post 2010 67 105.8 (74.5;150.3) 54 80.6 (69.1;89.2) 29/67 43.3 (31.2;56.0)
Kidney recipients Pre 2010 51 10.7 (7.5;15.4)** 10 19.6 (9.8;33.1) **
Post 2010 51 44.2 (28.5;68.7) 30 58.8 (44.2;72.4) 22/51 43.1 (29.3;57.8)
HAI : hemagglutination inhibition; 2010/2011 cohort: subjects followed in 2010/2011; 2009/2010/2011 cohort: subjects followed for 2 years.
Pre 2010: before 2010/2011 immunization; Post 2010:4 weeks after 2010/2011 immunization; Post 2009:4 weeks after 1.
*p,0.05, **p,0.01 and *** p,0.001 compared to controls.
doi:10.1371/journal.pone.0040428.t002
Memory Responses to Pandemic Influenza Vaccine
PLOS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e40428
Table 3. Determinants of vaccine antibody persistence and memory responses to influenza A/09/H1N1.
N Pre 2010 HAI-GMT (95%CI) Post 2010 HAI-GMT (95%CI)
Controls Age ,40 yrs 61 166.6 (120.2;230.8) 335.4 (258.4;435.2)
40-60 yrs 84 107.5 (85.7;134.9) 239.1 (190.8;299.5)
.60 yrs 11 46.1 (31.2;68.2) 107.0 (54.0;212.0)
p-value 0.001 0.005
Pre 2010 HAI-GMT , median 74 44.8 (40.3;49.9) 136.3 (111.0;167.3)
$ median 79 302.3 (251.7;363.0) 454.7 (373.2;554.1)
p-value ,0.001 ,0.001
HIV-infected
patients
Age ,40 yrs 44 98.7 (73.6;132.3) 634.6 (469.4;857.9)
40-60 yrs 123 107 (88.6;129.1) 516.5 (416.5;640.6)
.60 yrs 30 78.1 (51.3;118.7) 353.2 (219.4;568.5)
p-value 0.18 0.13
CD4 T cell count .= 350 163 110.5 (94.1;129.8) 518.2 (435.1;617.2)
,350 29 57.8 (38.8;86.0) 477.7 (259.9;878.2)
p-value 0.01 0.61
CD4 nadir .= 100 131 106.5 (88.8;127.8) 460.6 (381.3;556.4)
,100 65 88.4 (68.0;114.9) 617.9 (441.2;865.3)
p-value 0.29 0.02
CDC group A 89 93.1 (74.6;116.2) 421.0 (336.1;527.4)
B 51 130.5 (98.0;173.7) 515.6 (387.6;685.8)
C 56 88.3 (66.7;117.0) 667.6 (454.2;981.2)
p-value 0.12 0.04
HAART None 11 42.4 (28.5;63.0) 212.5 (109.1;413.9)
ART+NNRTI+PI 20 97.3 (59.4;159.4) 628.4 (408.7;966.4)
ART+NNRTI no PI 84 108.3 (86.2;136.0) 463.7 (364.0;590.7)
ART+PI no NNRTI 60 102.1 (77.3;134.7) 641.3 (450.7;912.6)
ART+Other 22 111.8 (74.7;167.4) 501.3 (318.0;790.1)
p-value 0.07 0.02
Pre 2010 HAI-GMT , median 96 43.0 (38.7;47.7) 336.9 (261.3;434.3)
$ median 100 225.7 (193.8;262.9) 754.3 (618.6;919.8)
p-value ,0.001 ,0.001
Kidney
recipients
Age ,40 yrs 3 263.8 (27.1;2568.0) 368.0 (34.6;3918.5)
40-60 yrs 21 69.1 (41.1;116.3) 130.5 (77.0;221.0)
.60 yrs 29 48.5 (32.5;72.4) 127.4 (66.7;243.6)
p-value 0.16 0.63
Tacrolimus No 16 44.5 (22.3;88.6) 178.3 (75.6;420.1)
Yes 37 70.6 (48.7;102.3) 121.4 (75.1;196.2)
p-value 0.27 0.20
MMF No 18 52.6 (30.2;91.8) 198.1 (96.0;408.9)
or EC-MPA Yes 35 66.5 (43.7;101.2) 113.9 (67.8;191.1)
p-value 0.78 0.17
Oral steroids No 25 59.5 (33.4;105.9) 95.4 (49.4;183.9)
Yes 28 63.2 (43.4;920) 188.9 (111.4;320.4)
p-value 0.85 0.17
Pre 2010 HAI-GMT , median 25 22.8 (16.7;31.2) 57.2 (32;102.2)
$ median 28 148.6 (109.4;201.8) 297.7 (191.1;463.8)
p-value ,0.001 ,0.001
Continuous variable were tested as categorical variable based on biological cut-off or on medians.
HAI : hemagglutination inhibition; 95%CI: 95% Confidence Interval; Pre 2010: before 2010/2011 immunization;
Post 2010:4 weeks after 2010/2011 immunization; PI: protease inhibitor; NNRTI : Non-Nucleoside Reverse.
Transcriptase Inhibitors; ART : antiretroviral therapy; HAART: highly active antiretroviral therapy;
MMF: mycophenolate mofetil; EC-MPA: enteric-coated mycophenolic acid.
doi:10.1371/journal.pone.0040428.t003
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competence, an exclusion recruitment criterion. As non-adju-
vanted influenza vaccines essentially reactivate pre-existing mem-
ory B cells, it suggests that in HCs 1 dose of PandemrixH drove
more B cells towards antibody-secreting plasma cells than memory
B cells.
It is thus quite remarkable that HIV and SOT patients
responded with higher titers to the non-adjuvanted 2010/2011
seasonal vaccine as to PandemrixH in 2009/2010. This is unlikely
to reflect higher immune competence: the CD4 counts of HIV
patients were not higher in 2010/2011 and the immunosuppres-
sion of SOT patients was essentially unchanged. Furthermore,
immune competence would not be higher in HIV/SOT patients
than in controls, in whom 2010/2011 responses remained lower.
As primary 2010/2011 responses to influenza A/09/H3N2 were
lower and not different among patients and controls, our
observations indicate a true enhancement of responses to the A/
09/H1N1 strain. Why did patients raise better memory responses
than healthy subjects? One key difference is that patients were
primed in 2009 with 2 doses and HC with 1 dose of PandemrixH.
This second primary dose implies an additional exposure to A/09/
H1N1 and to the AS03 adjuvant. Whether 2 doses of non-
adjuvanted H1N1 vaccine would increase subsequent memory
responses may not be excluded. But memory B-cells were indeed
reported as more numerous in HIV patients immunized with
PandemrixH than non-adjuvanted A/09/H1N1 vaccines [31].
Our field study was not planned to compare the influence of one
versus two doses of PandemrixH on memory responses, which
would not have been allowed by the Swiss authorities. Neverthe-
less, the most likely explanation to our observations is that 2 doses
of AS03-adjuvanted vaccines provided a more efficient induction
of memory responses than a single vaccine dose. This was
sufficient to overcome the potential deficiencies of the B cell
compartment caused by HIV infection. It even proved beneficial
in SOT patients, although their antibodies persisted/were
reactivated at lower levels than in HIV patients similarly primed
with 2 doses of adjuvanted pandemic vaccine, indicating lower
immune competence. That adjuvanted vaccines may improve
antibody persistence and memory responses of immunocompro-
mised patients is worth studying further.
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